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Objectives This study sought to investigate in vivo the vascular response at the proximal and distal
edges of the second-generation ABSORB everolimus-eluting bioresorbable vascular scaffold (BVS).
Background The edge vascular response after implantation of the BVS has not been previously in-
vestigated.
Methods The ABSORB Cohort B trial enrolled 101 patients and was divided into B1 (n  45) and
B2 (n  56) subgroups. The adjacent (5-mm) proximal and distal vessel segments to the implanted
ABSORB BVS were investigated at either 6 months (B1) or 1 year (B2) with virtual histology intravas-
cular ultrasound (VH-IVUS) imaging.
Results At the 5-mm proximal edge, the only signiﬁcant change was modest constrictive remodeling at
6 months (∆ vessel cross-sectional area: 1.80% [3.18; 1.30], p  0.05), with a tendency to regress at
year (∆ vessel cross-sectional area: 1.53% [7.74; 2.48], p  0.06). The relative change of the ﬁbrotic
nd ﬁbrofatty (FF) tissue areas at this segment were not statistically signiﬁcant at either time point. At
he 5-mm distal edge, a signiﬁcant increase in the FF tissue of 43.32% [19.90; 244.28], (p  0.05) 1-year
ost-implantation was evident. The changes in dense calcium need to be interpreted with caution since the
olymeric struts are detected as “pseudo” dense calcium structures with the VH-IVUS imaging modality.
onclusions The vascular response up to 1 year after implantation of the ABSORB BVS demonstrated
ome degree of proximal edge constrictive remodeling and distal edge increase in FF tissue resulting in
onsigniﬁcant plaque progression with adaptive expansive remodeling. This morphological and tissue
omposition behavior appears to not signiﬁcantly differ from the behavior of metallic drug-eluting stents
t the same observational time points. (J Am Coll Cardiol Intv 2012;5:656–65) © 2012 by the American
ollege of Cardiology Foundation
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657The vascular response at the stent edges has been evaluated
with first-generation drug-eluting stents and appears to be
dependent on the implanted device and the periprocedural
induced vascular trauma because of the geographic miss
(GM) phenomenon (1). The initial trial with the sirolimus-
eluting stent—RAVEL (RAndomized study with the
sirolimus-eluting VElocity balloon-expandable stent in the
treatment of patients with de novo native coronary artery
Lesions)—demonstrated no significant edge effect, presum-
ably due to the exceptional stent/lesion ratio of 2:1, due to
the sole availability of stent length (18 mm). A significant
proximal edge lumen loss was, however, observed in the
SIRIUS (Sirolimus-Coated Bx Velocity Balloon-
Expandable Stent in the Treatment of De Novo Native
Coronary Artery Lesions) trial, which evaluated the same
stent platform as in RAVEL, but with several stent lengths
and diameters of the device in a more complex population.
In the first-in-man TAXUS I trial, no edge effect was
demonstrated with the use of the slow-release polymer
formulation of the paclitaxel-eluting stent; conversely, in the
TAXUS II trial, the slow-release and moderate-release
polymer formulations of the paclitaxel-eluting stent resulted
in an edge lumen area loss (0.54 2.1 mm2 and0.88
.9 mm2, respectively) at both the proximal and distal stent
edges (2,3). In the BETAX (BEside TAXus) trial, using the
Taxus Express drug-eluting stent, significant tissue composi-
tional changes were observed, mainly due to an increase in
the fibrofatty (FF) tissue component causing expansive
remodeling at both stent edges (4).
Pre-clinical research has demonstrated that the tissue re-
sponse after stent implantation is exclusively composed of
From the *Thoraxcenter, Erasmus University Medical Center, Rotterdam, the
Netherlands; †Cardiovascular Center, Aalst, Belgium; ‡Institut Jacques Cartier,
Massy, France; §Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark;
Maasstad Hospital, Rotterdam, the Netherlands; ¶Jagiellonian University, Krakow,
Poland; #Catharina Hospital, Eindhoven, the Netherlands; **Bern University Hos-
pital, Bern, Switzerland; ††St. Vincent’s Hospital, Fitzroy, Australia; ‡‡Abbott
Vascular, Diegem, Belgium; §§Abbott Vascular, Santa Clara, California; Cardialy-
sis, Rotterdam, the Netherlands; ¶¶Christchurch Hospital, Christchurch, New
Zealand; and the ##Auckland City Hospital, Auckland, New Zealand. Dr. Gogas
wishes to acknowledge the American College of Cardiology Foundation for the
International Society of Cardiovascular Translational Research Award, and Hellenic
Cardiological Society and Hellenic Heart Foundation for providing funding support. Dr.
Chevalier is a consultant for Abbott Vascular. Prof. Dudek has received research grants or
served as consultant/advisory board member for Abbott, Adamed, AstraZeneca, Biotro-
nik, Balton, Bayer, BBraun, BioMatrix, Boston Scientific, Boehringer-Ingelheim, Bristol-
Myers Squibb, Cordis, Cook, Eli Lilly & Co., EuroCor, GlaxoSmithKline, Invatec,
Medtronic, The Medicines Company, MSD, Nycomed, Orbus-Neich, Pfizer, Possis,
Promed, Sanofi-Aventis, Siemens, Solvay, Terumo, and Tyco. Dr. Windecker received
research grants to the institution from Abbott, Biotronik, Biosensors, Boston Scientific,
and Cordis. Dr. Ormiston was on the advisory board of and received minor honoraria
from Abbott Vascular and Boston Scientific. Drs. Miquel-Hebert and Rapoza and Ms.
Dorange are employees of Abbott Vascular. Michael Kutcher, MD, served as Guest
Editor for this paper. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.s
Manuscript received September 29, 2011; revised manuscript received January 9,
2012, accepted February 14, 2012.proteoglycan-rich smooth muscle cells and fibrolipidic areas
rich in collagen and reticular fibers (5). This iatrogenic entity of
neointimal hyperplasia has been demonstrated to be usually
focal and most commonly located at the proximal stent edge
(6). The advent of scaffolds with bioresorbable properties and
iffering biological behavior compared with the currently used
etallic devices, has prompted the re-evaluation of the edge
ascular response using sound-based imaging modalities with
issue characterization properties. Such a modality is the virtual
istology intravascular ultrasound (VH-IVUS), which allows
or the evaluation of the vascular geometric changes and
ssessment of the atheromatous plaque progression/regression.
The purpose of this study is to investigate the edge effect
fter the implantation of the ABSORB bioresorbable vas-
ular scaffold (BVS) in the assessment of the geometric and
ompositional changes of the segments adjacent to the
-mm proximal and distal edges of the scaffolded vessel, in
population investigated at either 6 months or 1 year post
caffold implantation.
ethods
Study design and population.
The ABSORB Cohort B trial is
a multicenter, ongoing, single-
arm prospective, open-label trial
assessing the safety and perfor-
mance of the second-generation
ABSORB BVS in the treatment
of patients with a maximum of 2
de novo native coronary artery
lesions. In total, 101 patients
were enrolled and subdivided into
2 subgroups—Cohort B1 (n  45) and Cohort B2 (n 
56)—according to the predefined study design. Both groups
underwent invasive follow-up, Cohort B1 at 6 months and
Cohort B2 at 1 year. Cohort B1 is currently undergoing a
second VH-IVUS imaging of the scaffold edges at 2 -years and
Cohort B2 will undergo the final VH-IVUS imaging evalua-
tion at 3 years (Fig. 1).
In the present study, patients over the age of 18 years, who
had either stable or unstable angina pectoris or silent ischemia,
were suitable for inclusion. All treated lesions were de novo
lesions in a native coronary artery with a maximum diameter of
3.0 mm, a length of 14 mm, a percent diameter stenosis
50% and 100%, and a Thrombolysis In Myocardial In-
arction (TIMI) flow grade of 1. Major exclusion criteria
ere patients presenting with an acute myocardial infarction or
nstable arrhythmias, or patients who had a left ventricular
jection fraction 30%, restenotic lesions, lesions located in
he left main coronary artery, lesions involving an epicardial
ide branch 2 mm in diameter by visual assessment, and
he presence of thrombus or another clinically significant
Abbreviations
and Acronyms
CSA  cross-sectional area
DC  dense calcium
FF  fibrofatty
GM  geographic miss
NC  necrotic core
VH-IVUS  virtual histology
intravascular ultrasound
WSS  wall shear stresstenosis in the target vessel.
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658The ethics committee at each participating institution
approved the protocol, and each patient gave written in-
formed consent before inclusion.
Treatment device. The ABSORB BVS (Abbott Vascular,
anta Clara, California) is a balloon-expandable device con-
Figure 1. ABSORB Cohort B Study Design
The study design of the ABSORB Cohort B trial with the respective biological b
frames that virtual histology intravascular ultrasound (VH-IVUS) imaging was p
tive coronary angiography.
Table 1. Baseline Clinical and Lesion Characteristics
6 M
Proximal Edge
(n  23)
Age, yrs 62.41 9.86
Male 14 (61%)
Current smoking 3 (13.0%)
Diabetes 5 (22%)
Hypertension 16 (70%)
Hypercholesterolemia 22 (96%)
Prior myocardial infarction 8 (35%)
Unstable angina 3 (13%)
Stable angina 16 (70%)
Treated vessel
Right coronary artery 9 (39%)
Left anterior descending artery 6 (26%)
Left circumﬂex artery 7 (30%)
ACC/AHA lesion class:
Type A 1 (4%)
Type B1 10 (44%)
Type B2 11 (48%)
Type C 1 (4%)
RVD before intervention, mm 2.56 0.43
Values are mean SD or n (%).ACC/AHA American College of Cardiology/American Heart Association; Risting of a polymer backbone of poly-L-lactide coated with a
thin layer of a 1:1 mixture of poly-D,L-lactide. The polymer
controls the release of the antiproliferative drug everolimus,
and forms an amorphous drug-eluting coating matrix that
contains 100 g of everolimus/cm2 of scaffold. According to
or of the ABSORB bioresorbable vascular scaffold, at the different time
ed (yellow points). OCT  optical coherence tomography; QCA  quantita-
1 Year
Distal Edge
(n  18)
Proximal Edge
(n  24)
Distal Edge
(n  29)
64.70 9.83 59.21 7.72 60.20 7.72
12 (67%) 15 (63%) 20 (69.0%)
1 (6%) 5 (21%) 2 (7%)
3 (17%) 7 (29%) 6 (21%)
13 (72%) 17 (74%) 19 (68%)
18 (100%) 18 (75%) 22 (76%)
7 (39%) 5 (21%) 3 (11%)
3 (17%) 4 (17%) 6 (21%)
14 (78%) 14 (58%) 17 (59%)
7 (39%) 9 (36%) 8 (27%)
6 (33%) 10 (40%) 16 (53%)
4 (22%) 6 (24%) 6 (20%)
1 (5%) 0 (0%) 0 (0%)
9 (50%) 17 (71%) 22 (73%)
8 (44%) 6 (25%) 7 (23%)
0 (0%) 1 (4%) 1 (3%)
2.78 0.45 2.61 0.33 2.50 0.28ehavi
erformonthsVD reference vessel diameter.
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659bench studies, the ABSORB BVS device has shown a dynamic
biological behavior at 6 months, 1 year, and 2 years, at which
time the complete bioresorption of the polymer backbone is
expected (7).
At 6 months, a gradual and steep loss of the device radial
trength in parallel to the continuous decrease of the device
Table 3. Summary of the Proximal and Distal Edge Changes at 6 Months a
Vessel CSA (mm2) Lumen CSA (mm2) Pla
Proximal Edge 6 Months (n  23)
Baseline 13.2 [10.81; 15.90] 7.15 [5.80; 8.65] 5
Follow-up 13.38 [10.26; 15.39] 7.15 [5.60; 8.41] 5
Median absolute difference 0.25 [0.54; 0.18] 0.27 [0.78; 0.67] 0
p value <0.05 NS
Distal Edge 6 Months (n  18)
Baseline 12.79 [10.17; 16.38] 7.27 [5.62; 7.90] 7.0
Follow-up 13.87 [10.42; 16.15] 6.85 [6.11; 8.44] 6.0
Median absolute difference 0.07 [0.51; 1.00] 0.03 [0.55; 0.58] 0.3
p value NS NS
Values are medians (interquartile ranges). Analysis was performed at the lesion level.
Table 2. Summary of the % Changes of the Entire 5-mm Segment, at the P
Plaque Composition Parameters 6 Months and 1 Year Following Implantat
Vessel CSA (mm2)
Proximal edge segment, (%) change
6 months (n  23) 1.8 [3.18; 1.30]
p value <0.05
1 year (n  25) 1.53 [7.74; 2.48]
p value NS
Distal edge segment, (%) change
6 months (n  18) 0.59 [3.74; 7.09]
p value NS
1 year (n  30) 3.45 [2.08; 6.91]
p value NS
Dense Calcium (mm2)
Proximal edge segment, (%) change
6 months (n  23) 12.02 [31.62; 47.50]
p value NS
1 year (n  25) 7.91 [42.19; 17.26] 
p value NS
Distal edge segment, (%) change
6 months (n  18) 44.09 [22.81; 159.23]
p value <0.05
1 year (n  30) 20.57 [50.22; 54.11] 1
p value NS
p values in bold are statistically significant.
BVS bioresorbable vascular scaffold; CSA cross-sectional area; NS not significant.Abbreviations as in Table 2.olecular weight is observed because of the depolymeriza-
ion and hydrolysis after implantation. The molecular
eight of the polymeric platform continues to decrease until
year, when the radial strength is completely eliminated,
nd the device represents a passive structure without any
upportive vascular properties. At 2 years, the ABSORB
Year After Implantation of the ABSORB BVS
After the Imaging Procedure
A (mm2) Vessel CSA (mm2) Lumen CSA (mm2) Plaque CSA (mm2)
1 Year (n  25)
2; 7.08] 13.89 [12.55; 17.24] 7.25 [6.44; 8.40] 7.02 [5.52; 7.80]
6; 7.25] 13.71 [12.22; 16.11] 7 [6.14; 8.30] 7.08 [5.36; 8.38]
0.63; 0.60] 0.19 [1.06; 0.33] 0.35 [0.77; 0.25] 0.15 [0.59; 0.37]
S NS NS NS
1 Year (n  30)
; 7.89] 10.28 [9.13; 13.46] 6.7 [5.63; 7.80] 4.47 [2.29; 5.61]
; 8.40] 10.49 [9.88; 13.33] 6.76 [5.56; 7.78] 4.46 [3.20; 6.61]
82; 0.97] 0.4 [0.26; 0.63] 0.09 [0.49; 0.43] 0.27 [0.27; 0.97]
NS NS NS
al and Distal Edges, Regarding Geometric and
the ABSORB BVS
Lumen CSA (mm2) Plaque CSA (mm2)
4.1 [11.61; 8.79] 4.04 [10.65; 11.05]
NS NS
5.32 [12.36; 4.24] 2.03 [8.39; 7.76]
NS NS
0.32 [7.71; 7.20] 7 [11.97; 18.36]
NS NS
0.95 [7.56; 7.48] 5.73 [6.49; 25.47]
NS NS
ibrous (mm2) Fibrofatty (mm2) Necrotic Core (mm2)
16.83; 67.23] 10.3 [46.38; 134.69] 24.14 [22.32; 76.76]
NS NS NS
20.03; 11.86] 9 [36.77; 87.41] 4.35 [31.23; 30.40]
NS NS NS
18.83; 107.39] 8.21 [37.77; 91.48] 23.59 [19.89; 74.33]
NS NS NS
11.14; 108.93] 43.32 [19.90; 244.28] 6.25 [44.20; 81.94]
NS <0.05 NSnd 1
Time
que CS
.88 [4.2
.49 [3.8
.25 [
N
2 [4.15
7 [4.90
5 [0.
NSroxim
ion of
F
4.44 [
2.58 [
4.07 [
8.87 [
p
a
y
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660BVS is considered fully resorbed, having been metabolized
into CO2 and H2O through the Krebs cycle (Fig. 1). This
dynamic behavior of the polymeric device at the above-
mentioned time points prompts the in vivo evaluation of the
vascular response at the scaffold edges with VH-IVUS
imaging in parallel to its evolving biological behavior (8).
Treatment procedure. Lesions were treated with routine
interventional techniques that included mandatory pre-
dilation with a balloon shorter and 0.5 mm smaller in
diameter than the study device. The ABSORB BVS was
implanted at a pressure not exceeding the rated burst
pressure (16 atm). Post-dilation with a balloon shorter than
the implanted device was allowed at the discretion of the
operator, as was bailout treatment.
Quantitative IVUS and VH-IVUS analysis. Geometric param-
eters in the complete 5-mm proximal and distal segments
derived from the grayscale IVUS and VH-IVUS acquisition
were analyzed in each separate frame—that is, vessel area,
lumen area, plaque area, and tissue composition parame-
ters—as absolute values. Furthermore, percentages were
assessed for each cross section in the same region of interest.
Both the proximal and distal vessel segments were further
divided into 1-mm subsegments, numbered from 1 (adja-
cent to the scaffold) to 5, and underwent similar imaging
evaluation as for the complete segment.
The tissue compositional analysis was obtained with a
phased-array 20-MHz intravascular ultrasound catheter
(Eagle Eye, Volcano Corporation, Rancho Cordova, Cali-
fornia) after intracoronary administration of 100 to 200 g
of nitroglycerin, using automated pullback at 0.5 mm/
second (30 frames/s). The raw radiofrequency data were
capture gated to the R-wave. The main principle of the
VH-IVUS imaging technique is that both the envelope
amplitude of the reflected radiofrequency signals, as under-
taken with standard grayscale IVUS analyses, and the
underlying frequency content is used to analyze the tissue
components present in coronary plaques. The combined
Table 4. Summary of the Tissue Composition Changes at the Proximal and
Dense Calcium (mm2)
Proximal edge segment (n  25)
Baseline 0.48 [0.24; 0.76]
1-year follow-up 0.33 [0.24; 0.54]
Median absolute difference 0.02 [0.20; 0.09]
p value NS
Distal edge segment (n  30)
Baseline 0.18 [0.08; 0.57]
1-year follow-up 0.19 [0.08; 0.31]
Median absolute difference 0.02 [0.20; 0.07]
p value NS
p values in bold are statistically significant.
Abbreviations as in Table 3.information is subsequently processed using autoregressivemodels and thereafter categorized into a classification tree
that determines the 4 basic plaque tissue components: 1)
fibrous tissue—dark green; 2) FF—light green; 3) necrotic
core (NC)—red; and 4) dense calcium (DC)—white (9). All
VH-IVUS analyses were performed offline using the pcVH
2.1 software (Volcano Corporation) by an independent
clinical research organization (Cardialysis, Rotterdam, the
Netherlands). At 6 months (Cohort B1, n  45), 23
roximal and 18 distal edge segments were suitable for
nalysis with grayscale IVUS and VH-IVUS imaging. At 1
ear (Cohort B2, n  56), 25 proximal and 30 distal edge
segments were analyzable. The reasons for the reduced
number of our final tested samples were: 1) the dropout of
patients at follow-up (the attrition rate of the ABSORB
Cohort B trial was 20%) and exclusion of the unpaired
samples from our final data; and 2) exclusion of cases,
according to the standard operational procedure of the
independent core laboratory (Cardialysis), with side-branch
outgrowth of 90° at the side of the scaffold edge that did
not allow the analysis of the complete 5-mm segment and
vessel wall out of the field of the view.
Statistical analysis. Discrete variables are presented as
counts and percentages. Continuous variables are pre-
sented as medians and interquartile ranges. Comparison
between baseline and follow-up was performed using the
Wilcoxon signed rank test. Changes (differences) for each
measurement were calculated as follow-up minus post-
procedure values. Percent changes (differences) for each
variable were calculated as follow-up post-procedure/
post-procedure 100%. A p value 0.05 was considered
statistically significant. Data analyses were performed
with SAS version 9.1 software (SAS Institute, Cary,
North Carolina).
Results
The baseline clinical and lesion characteristics of the pa-
l Edges, 1 Year After Implantation of the ABSORB BVS
Dense Calcium (%) Fibrous (mm2)
12.55 [7.02; 20.20] 1.95 [1.01; 2.69]
11.97 [8.31; 17.94] 2.02 [1.37; 2.41]
0.72 [3.70; 4.65] 0.04 [0.33; 0.20]
NS NS
15.87 [10.17; 35.30] 0.91 [0.08; 1.61]
10.5 [6.93; 17.07] 0.9 [0.28; 1.52]
4.22 [12.18; 1.35] 0.09 [0.07; 0.22]
<0.05 NSDistatients are demonstrated in Table 1. The percent (%) changes
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661(median [interquartile range]) of the vessel cross-sectional
area (CSA), lumen CSA, and plaque CSA at the 5-mm
proximal edge segment were at 6 months: 1.80% [3.18;
1.30], (p  0.05), 4.10% [11.61; 8.79], (p  0.22), and
4.04% [10.65; 11.05] (p 0.55); and at 1 year:1.53%
[7.74; 2.48], (p  0.06), 5.32% [12.36; 4.24], (p 
0.07), and 2.03% [8.39; 7.76], (p  0.72), respectively.
The % changes of the vessel CSA, lumen CSA, and plaque
CSA at the 5-mm distal edge segment were at 6 months:
0.59% [3.74; 7.09], (p  0.71), 0.32% [7.71; 7.20],
Table 4. Continued
Fibrous (%) Fibrofatty (mm2) Fibrof
55.08 [46.10; 63.52] 0.26 [0.11; 0.45] 7.34 [4.9
53.62 [48.56; 59.95] 0.28 [0.09; 0.38] 8 [4.4
0.1 [4.67; 5.71] 0.01 [0.10; 0.19] 0.03 [
NS NS N
54.72 [35.05; 62.19] 0.06 [0.01; 0.17] 4.7 [2.4
57.75 [51.27; 62.42] 0.1 [0.03; 0.28] 8.1 [4.2
1.83 [4.36; 14.58] 0.02 [0.00; 0.09] 2.24 [0.4
NS <0.05 <
Figure 2. Grayscale IVUS and Corresponding VH-IVUS Still Frames at 1-Yea
(A) Distal edge segment. At this segment a signiﬁcant increase of the ﬁbrofatt
sue area from 0.07 to 0.14 mm2. Dense calcium (DC) and necrotic core tissue
respectively, as a consequence of the bioresorption process. (B) Scaffolded seg
rounded by a red, halo. (C) Proximal edge segment. At this segment some de
IVUS shows for this frame a change in the lumen area from 9.4 mm2 to 8.4 m
branch, [yellow asterisk]).(p  0.97), and 7.0% [11.97; 18.36], (p  0.50); and at 1
year: 3.45% [2.08; 6.91], (p 0.07), 0.95% [7.56; 7.48],
(p  0.77), and 5.73% [6.49; 25.47], (p  0.09), respec-
tively (Table 2). The absolute geometric and tissue compo-
sition changes and the subsegmental analysis at 1 year are
tabulated in (Tables 3 and 4) and illustrated in Figs. 2, 3, and 4.
The absolute tissue compositional changes at 6 months
at both edges and the subsegmental analysis at the same
time point are tabulated and illustrated in the Online
Appendix.
) Necrotic Core (mm2) Necrotic Core (%)
6] 0.85 [0.40; 1.28] 19.63 [17.16; 29.81]
9] 0.64 [0.42; 1.01] 20.49 [15.11; 29.02]
42] 0.06 [0.32; 0.23] 2.05 [5.58; 5.65]
NS NS
] 0.4 [0.04; 0.72] 21.96 [17.58; 28.00]
4] 0.3 [0.09; 0.64] 18.75 [14.65; 24.88]
] 0.01 [0.33; 0.09] 2.82 [7.26; 4.22]
NS NS
r Implantation of the ABSORB BVS
tissue was observed. VH-IVUS demonstrates at this frame a change in FF tis-
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. The polymeric struts of the ABSORB BVS are detected as “pseudo” DC sur-
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662Discussion
The main findings of this study at the time point of 1-year
post-implantation of the ABSORB BVS are as follows.
Constrictive vascular remodeling at the proximal edge was
evident without significant changes in tissue composition
parameters. At the distal edge, tissue composition changes
were evident with a significant increase in the FF tissue
resulting in nonsignificant plaque progression and adaptive
expansive remodeling (Fig. 2).
The edge effects following the implantation of either a
metallic or a polymeric device have common etiological mech-
anisms, namely: 1) periprocedural or iatrogenic technical issues
affecting predominantly geometric parameters (1–11); 2) tissue
composition characteristics of the lesion (12); and 3) local wall
shear stress (WSS) conditions (13–15).
The GM phenomenon, associated with sirolimus-eluting
stent implantation, was investigated in the STLLR (Stent
Deployment Techniques on Clinical Outcomes of Patients
Treated With the Cypher Stent) study and was reported to
occur in nearly two-thirds (66.5%) of the study group;
almost one-half of the patients (47.6%) experienced longi-
tudinal GM, over one-third (35.2%) axial GM, and 16.5%,
a combination of the 2 (1,10). Hoffmann et al. (10)
demonstrated within the E-SIRIUS (European, multi-
center, randomized, double blind trial of the
SIRolImUS-coated Bx-Velocity stent in the treatment of
Figure 3. Subsegmental Analysis of the Geometric Changes at the Proxima
The analysis, per mm of the subsegments, was performed at 1-year follow-up.patients with de novo coronary artery lesions)-IVUS hsubstudy versus the SIRIUS-US (US, multicenter, ran-
domized, double blind trial of the SIRolImUS-coated
Bx-Velocity stent in the treatment of patients with de
novo coronary artery lesions) trial, that both axial and
longitudinal GM were reduced (from 5.9% to 2.1%)
when periprocedural implantation parameters were taken
into account, such as conservative pre-dilation, less force-
ful stent implantation (16 atm), and selective post-
dilation with balloons shorter than the stent.
Despite multiple technical guidelines regarding the ABSORB
BVS delivery system to minimize the axial (burst pressure:
16 atm) and longitudinal (balloon shorter and 0.5 mm
smaller than the implanted device) GM phenomena, a
significant proximal edge constrictive response was demon-
strated at 6 months, whereas at 1 year, the constrictive
remodeling was only observed in the following proximal
subsegments, starting from the scaffold edge (subsegment 1: 
0.96 mm2, (p  0.05); subsegment 2:  0.71 mm2, (p 
.05); and subsegment 4:  0.57(p  0.05) (Figs. 3 and 4).
The changes in WSS distribution adjacent to the stent
dges post device implantation appear to follow alterations
n vessel curvature and angulation, and have been reported
o result in step-up regions of low shear stress, prone to
eointimal growth (13–15).
Metallic devices have a more accentuated effect on vessel
urvature and angulation compared to the ABSORB BVS;
Distal Edges After Implantation of the ABSORB BVS
bioresorbable vascular scaffold.l andowever, despite the clinical benefits associated with better
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663conformability (16) of the ABSORB BVS device, proximal
constrictive remodeling was observed at 1-year after
implantation, and further investigations are required to
evaluate the changes of WSS at the scaffold edges or the
in-scaffold area. Moreover, any of the initial flow–tissue
interaction effects caused by the implantation of this
bioresorbable device are expected to potentially subside
after a 2-year period when the bioresorption process is
expected to be complete and the polymeric platform is
fully transformed to CO2 and H2O, with no consequent
emaining compliance mismatch (8,16). Samady et al.
17) recently demonstrated, in a cohort of 20 patients,
hat coronary segments with low WSS (step-up regions)
re segments that develop constrictive remodeling, in
ontrast to the high-WSS segments that present exces-
ive expansive remodeling with tissue composition
hanges, mainly due to an increase in DC and NC tissue
omponents. These reported observations are in parallel
ith the present findings in this study regarding vessel
eometry and tissue composition.
The distal edge segment adjacent to the scaffold appeared
o have major tissue composition changes with some degree
f plaque progression, which caused a subsequent nonsig-
ificant expansive remodeling. The VH-IVUS–derived tis-
ue type that correlates with extracellular matrix is the FF
issue, which happens to be the one that increased the most
18). The DC tissue component appeared to have a biphasic
Figure 4. Subsegmental Analysis of the Tissue Composition Changes at th
The analysis, per mm of the subsegments, was performed at 1-year follow-up.esponse at this segment after the ABSORB BVS implan- eation with a significant increase at 6 months and a trend
oward a decrease at 1-year follow-up; conversely, the NC
issue changed nonsignificantly following sequential modi-
cations of DC tissue.
The changes in DC and NC tissue components at
ollow-up should be interpreted with caution since the
BSORB BVS is made of bioresorbable polymeric material
ecognized as “pseudo” DC and NC, parameters that have
reviously been reported as surrogate markers of the biore-
orption process (19,20). In addition, the edges of the
olymeric scaffold are not sharply demarcated since the
essel surrounding the imaging device are affected by the “to
nd fro” motion of the cardiac contraction, causing a
pseudoaxial” displacement of the IVUS catheter related to
he arterial wall.
Indeed, the cardiac cycle can cause a mean axial displace-
ent of the IVUS transducer of 1.5 mm with a maximum
istortion up to 6.5 mm; however, the use of electrocardio-
ram gating during IVUS data acquisition reduces the
xial movement to a maximum of 0.8 mm (21–23) but
oes not fully prevent the imaging of the polymeric struts
s “pseudo” DC in the adjacent edge of the implanted
evice. In keeping with the standard operational proce-
ure of an independent core laboratory (Cardialysis), the
uantification of the scaffold edges was initiated at the
oint where the visualization of the scaffold arc at each
rame was 360°, implying that the scaffold edge to some
imal and Distal Edges After Implantation of the ABSORB BVS
bioresorbable vascular scaffold.e Proxxtent may include polymeric struts.
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664The apparent increase in DC at 6 months, followed by a
trend toward a reduction at 1 year, accompanied by the
parallel behavior of the NC, are attributed to the introduc-
tion of the bioresorbable device during the procedure and
subsequent bioresorption process long term. Other possible
factors that may have influenced the NC tissue component
are the locally eluted drug everolimus and the systemic use
of HMG-CoA inhibitors. Verheye et al. (24) recently
demonstrated that everolimus—an inhibitor of the mam-
malian target of rapamycin (m-TOR)—has autophagic
capabilities on macrophages, with a subsequent effect of
diminishing NC formation, inflammation, and thrombosis.
Hong et al. (25) reported a significant 13% relative reduc-
tion in plaque necrotic core volume, and a significant 27%
relative increase in plaque FF content with the administra-
tion of HMG-CoA inhibitors, assessed with VH-IVUS at
1-year follow-up.
Coronary endothelial dysfunction has been previously
associated with underlying plaque composition, in particular
high content of DC and NC. Lavi et al. (26) have
demonstrated impaired endothelial-dependent vasomotion
in vessel segments with underlying NC-rich plaques. Our
group has recently demonstrated that the restored normal
vasodilatory response to acetylcholine in coronary segments
that have previously undergone implantation with an AB-
SORB BVS, is associated with a reduction of NC (27),
implying the potential restoration of the vasomotor function
of the treated vessel with reductions of specific tissue
components. Whether the present findings are due to the
combined effects of locally eliminated m-TOR inhibitor
everolimus, with the systemic use of the HMG-CoA
inhibitors, or the natural history of the bioresorbable
process of the implanted device, remains to be elucidated
in future studies, where a potential restoration of the
vasomotor function at the scaffold edges would be highly
expected with the sustained tissue composition changes
observed at 1-year follow-up. Furthermore, the combi-
nation of continuous polymer degradation and elabora-
tion of the treated vessel from its foreign material beyond
1 year, with the restoration of vessel biological behavior
(vasomotor function) and the interplay with pharmaco-
logical intervention may potentially eliminate the risk of
late stent thrombosis.
The clinical outcome of the ABSORB Cohort B trial at
1-year post implantation of the ABSORB BVS revealed a
hierarchical major adverse cardiac event rate of 6.9%, with
no episodes of scaffold thrombosis (according to the proto-
col or Academic Research Consortium definitions). Pre-
scaffolding VH-IVUS analysis can give an insight into the
extent of plaque and NC within and beyond the intended
scaffolded segment. This latter point is potentially impor-
tant, since full coverage of the lesion by the implanted
device is the desired goal of the interventionalist, as incom-
plete coronary plaque coverage has been reported to effectlong-term clinical events, especially in the presence of
NC-containing plaques (11).
Study limitations. The main limitation of our study is the
mall number of the investigated scaffold edges. The complete
ohort (B1	B2) at the different time points without splitting
the population would potentially have increased the sample
size; this, however, was a predefined design of the study.
Conclusions
The edge vascular response, with the use of the ABSORB
BVS device at 1-year post implantation, demonstrates a
degree of proximal edge constrictive remodeling and distal
edge plaque compositional changes, a biological behavior
similar to that observed with the metallic devices. Full
bioresorption of the device, expected to occur in approxi-
mately 2 years, will potentially allow for the evaluation and
comparison of the exact biological composition of the
treated vessel at the scaffold edges, utilizing the VH-IVUS
imaging modality.
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